We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Astrazeneca (AZN) Stock Falls Amid Market Uptick: What Investors Need to Know
Read MoreHide Full Article
In the latest close session, Astrazeneca (AZN - Free Report) was down 1.17% at $69.26. This move lagged the S&P 500's daily gain of 0.54%. Elsewhere, the Dow saw an upswing of 0.52%, while the tech-heavy Nasdaq appreciated by 0.74%.
The pharmaceutical's shares have seen a decrease of 0.96% over the last month, surpassing the Medical sector's loss of 2.12% and falling behind the S&P 500's gain of 4.2%.
Market participants will be closely following the financial results of Astrazeneca in its upcoming release. The company plans to announce its earnings on July 29, 2025. In that report, analysts expect Astrazeneca to post earnings of $1.1 per share. This would mark year-over-year growth of 11.11%. Meanwhile, our latest consensus estimate is calling for revenue of $14.03 billion, up 8.42% from the prior-year quarter.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $4.5 per share and a revenue of $57.68 billion, indicating changes of +9.49% and +6.67%, respectively, from the former year.
Investors should also take note of any recent adjustments to analyst estimates for Astrazeneca. These revisions help to show the ever-changing nature of near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.11% downward. Astrazeneca is currently a Zacks Rank #3 (Hold).
Valuation is also important, so investors should note that Astrazeneca has a Forward P/E ratio of 15.59 right now. This signifies a discount in comparison to the average Forward P/E of 18.38 for its industry.
It is also worth noting that AZN currently has a PEG ratio of 1.29. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The Medical - Biomedical and Genetics industry currently had an average PEG ratio of 1.55 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 83, positioning it in the top 34% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Astrazeneca (AZN) Stock Falls Amid Market Uptick: What Investors Need to Know
In the latest close session, Astrazeneca (AZN - Free Report) was down 1.17% at $69.26. This move lagged the S&P 500's daily gain of 0.54%. Elsewhere, the Dow saw an upswing of 0.52%, while the tech-heavy Nasdaq appreciated by 0.74%.
The pharmaceutical's shares have seen a decrease of 0.96% over the last month, surpassing the Medical sector's loss of 2.12% and falling behind the S&P 500's gain of 4.2%.
Market participants will be closely following the financial results of Astrazeneca in its upcoming release. The company plans to announce its earnings on July 29, 2025. In that report, analysts expect Astrazeneca to post earnings of $1.1 per share. This would mark year-over-year growth of 11.11%. Meanwhile, our latest consensus estimate is calling for revenue of $14.03 billion, up 8.42% from the prior-year quarter.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $4.5 per share and a revenue of $57.68 billion, indicating changes of +9.49% and +6.67%, respectively, from the former year.
Investors should also take note of any recent adjustments to analyst estimates for Astrazeneca. These revisions help to show the ever-changing nature of near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.11% downward. Astrazeneca is currently a Zacks Rank #3 (Hold).
Valuation is also important, so investors should note that Astrazeneca has a Forward P/E ratio of 15.59 right now. This signifies a discount in comparison to the average Forward P/E of 18.38 for its industry.
It is also worth noting that AZN currently has a PEG ratio of 1.29. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The Medical - Biomedical and Genetics industry currently had an average PEG ratio of 1.55 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 83, positioning it in the top 34% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.